HIV treatment: Difference between revisions
From IDWiki
No edit summary |
(→) |
||
| Line 51: | Line 51: | ||
**[[Tenofovir]]/[[lamivudine]] + other |
**[[Tenofovir]]/[[lamivudine]] + other |
||
**[[Tenofovir]]/[[emtricitabine]] + other |
**[[Tenofovir]]/[[emtricitabine]] + other |
||
| + | *If cannot use [[tenofovir]] (severe renal or hepatic dysfunction), then add [[entecavir]] to the HIV regimen |
||
===Hepatitis C Coinfection=== |
===Hepatitis C Coinfection=== |
||
| Line 72: | Line 73: | ||
===Cryptococcal Meningitis=== |
===Cryptococcal Meningitis=== |
||
| − | *Delay treatment for risk of IRIS |
+ | *Delay treatment for risk of [[Immune reconstitution inflammatory syndrome|IRIS]] |
==Switching Regimens== |
==Switching Regimens== |
||
Revision as of 10:25, 22 October 2020
When to Start
- Start in all viremic patients regardless of CD4 count and in all patients with declining CD4 regardless of viremia
- Start as soon as possible in patients with acute HIV, as it decreases the HIV reservoir
- Less loss-to-follow-up, time-to-virologic-suppression decreased
- Rapid linkage to care within 5 working days of diagnosis
- Do not stop treatment
- Unclear whether treatment needed for elite controllers
- Only delay treatment in:
- Cryptococcal meningitis, which should be delayed by 2 to 10 weeks
- Tuberculosis
- CD4 <50 cells/mL: start within 2 weeks
- CD4 ≥50 cells/mL: start within 8 weeks
- Tuberculous meningitis: start within 2 to 8 weeks
Starting Treatment
- Arrange their first clinic visit, and do the appropriate investigations
- Choose an appropriate single-tablet regimens, and start
- Preference for regimen that includes integrase inhibitor
- Book follow-up
Antiretroviral Therapy (ART) Regimens
- Refer to HIV medications for information about specific medications
- In general, use two nucleoside reverse-transcriptase inhibitors (NRTIs) and one non-NRTI (usually an integrase inhibitor)
- Preference for single-tablet regimens for HIV, which improve adherence
- Recommended first-line regimens include:
- Bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy)
- Dolutegravir/abacavir/lamivudine (Triumeq), only for individuals who are HLA-B*5701 negative and without chronic hepatitis B virus (HBV) coinfection
- Dolutegravir plus (emtricitabine or lamivudine) plus (tenofovir alafenamide or tenofovir disoproxil fumarate)
- Dolutegravir/lamivudine (Dovato), except for individuals with HIV RNA >500,000 copies/mL, HBV co-infection, or in whom ART is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available.
- Raltegravir plus (emtricitabine or lamivudine) plus (tenofovir alafenamide or tenofovir disoproxil fumarate)
Special Populations
Pregnancy
- Treat!
- NRTI backbone: abacavir/lamivudine, tenofovir/emtricitabine, or tenofovir/lamivudine
- 3rd agent
- Protease inhibitor: ATV/r or DRV/r
- Raltegravir
- Avoid dolutegravir, may cause neural tube defects when on it at the time of conception (but not if started during pregnancy)
Hepatitis B Coinfection
- Absolutely prefer regimen containing tenofovir
- Ideally, use tenofovir, lamivudine or emtricitabine, and a third agent
- Tenofovir/lamivudine + other
- Tenofovir/emtricitabine + other
- If cannot use tenofovir (severe renal or hepatic dysfunction), then add entecavir to the HIV regimen
Hepatitis C Coinfection
- See also HIV-Hepatitis C coinfection for details
- In general, there's no need to delay either treatment; they can be treated concurrently
- Beware significant interactions with HCV medications
- Avoid elvitegravir/cobicistat whenever possible, as it interacts with most regimens
- Sofosbuvir can increase TDF (though not TAF) levels
Tuberculosis
- Probably don't need to wait to treat
- Avoid TAF if using rifampin/rifamycin
- If using rifampin
- Efavirenz probably the best option
- Raltegravir needs dose increase to 800 mg BID
- Dolutegravir 50 mg BID only without selected INSTI mutations
- If using PI, rifabutin can be used instead of rifampin
Cryptococcal Meningitis
- Delay treatment for risk of IRIS
Switching Regimens
- May be indicated to simplify regimens (single-pill), interactions, tolerability, comorbidities, pregnancy, or cost
- Goal is to maintain viral suppression to avoid resistance
- Consider:
- Previous exposure to ART
- Previous pattersn of resistance
- Likelihood of adherence
- Drug-drug and drug-food interactions
- Comorbidities
- Can switch within- or between-class
- Within-class
- EFV to RPV
- RAL to EVG or DTG
- DTG to BIC
- TDF or ABC to TAF
- Between-class
- Boosted PI to RPV
- Boosted PI to EVG, DTG, or BIC
- NNRTI to EVG or DTG
- Within-class
- TDF to TAF may see an increase in cholesterol
Side Effects
- Kidney problems
- Metabolic complications
- Osteoporosis
- Dyslipidemia
- Cardiovascular disease
References
- ^ Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. New England Journal of Medicine. 2015;373(9):795-807. doi:10.1056/nejmoa1506816.
- ^ A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. New England Journal of Medicine. 2015;373(9):808-822. doi:10.1056/nejmoa1507198.
